Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: A meta-analysis of randomised trials

The Lancet

Volumn 385, Issue 9971, 2015, Pages 867-874

  Agodoa, L ^a   Estacio, R ^a   Schrier, R ^a   Lubsen, J ^a   Chalmers, J ^a   Cutler, J ^a   Davis, B ^a   Wing, L ^a   Poulter, N R ^a   Sever, P ^a   Remuzzi, G ^a   Ruggenenti, P ^a   Nissen, S ^a   Lindholm, L H ^a   Fukui, T ^a   Ogihara, T ^a   Saruta, T ^a   Black, H ^a   Sleight, P ^a   Lievre, M ^a   Suzuki, H ^a   Fox, K ^a   Lisheng, L ^a   Ohkubo, T ^a   Imai, Y ^a   Yusuf, S ^a   Bulpitt, C J ^a   Lewis, E ^a   Brown, M ^a   Palmer, C ^a   Wang, J ^a   Pepine, C ^a   Ishii, M ^a   Yui, Y ^a   Kuramoto, K ^a   Pfeff Er, M ^a   Asselbergs, F W ^a   Van Gilst, W H ^a   Byington, B ^a   Pitt, B ^a   Brenner, B ^a   Remme, W J ^a   De Zeeuw, D ^a   Rahman, M ^a   Viberti, G ^a   Teo, K ^a   Zanchetti, A ^a   Malacco, E ^a   Mancia, G ^a   Staessen, J ^a   Fagard, R ^a   Holman, R ^a   Hansson, L ^a   Kostis, J ^a   Kanno, Y ^a   Lueders, S ^a   Matsuzaki, M ^a   Poole Wilson, P ^a   Schrader, J ^a   Rahimi, K ^a   Anderson, C ^a   Chapman, N ^a   Collins, R ^a   MacMahon, S ^a   Neal, B ^a   Rodgers, A ^a   Whelton, P ^a   Woodward, M ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO;

ARTICLE; BODY MASS; CARDIOVASCULAR RISK; DRUG EFFICACY; HEART DEATH; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; RISK REDUCTION;

ANTIHYPERTENSIVE AGENTS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK REDUCTION BEHAVIOR;

EID: 84924254084     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61171-5     Document Type: Article

References (42)

1. SS Lim, T Vos, AD Flaxman et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2224 2260
2. HM Shihab, LA Meoni, AY Chu et al. Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study Circulation 126 2012 2983 2989
3. S Czernichow, K Castetbon, B Salanave et al. Determinants of blood pressure treatment and control in obese people: evidence from the general population J Hypertens 30 2012 2338 2344
4. F Turnbull Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 362 2003 1527 1535
5. MR Law, JK Morris, NJ Wald Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ 338 2009 b1665
6. B Neal, S MacMahon, N Chapman Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration Lancet 356 2000 1955 1964
7. K Silventoinen, PKE Magnusson, M Neovius et al. Does obesity modify the effect of blood pressure on the risk of cardiovascular disease? Circulation 118 2008 1637 1642
8. R Tsukinoki, Y Murakami, R Huxley et al. Does body mass index impact on the relationship between systolic blood pressure and cardiovascular disease? Stroke 43 2012 1478 1483
9. M Chrostowska, R Szczech, K Narkiewicz Antihypertensive therapy in the obese hypertensive patient Curr Opin Nephrol Hypertens 15 2006 487 492
10. JAN Dorresteijn, FLJ Visseren, W Spiering Mechanisms linking obesity to hypertension Obesity Rev 13 2012 17 26
11. GZ Kalil, WG Haynes Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications Hypertens Res 35 2012 4 16
12. S Czernichow, T Ninomiya, R Huxley et al. Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial Hypertension 55 2010 1193 1198
13. K Nakao, M Hirata, K Oba et al. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial Hypertens Res 33 2010 600 606
14. G de Simone, K Wachtell, V Palmieri et al. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study Circulation 111 2005 1924 1931
15. LMA Kennedy, SD Anker, J Kjekshus, TJ Cook, R Willenheimer Impact of neurohormonal blockade on association between body mass index and mortality Int J Cardiol 119 2007 33 40
16. MA Weber, K Jamerson, GL Bakris et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial Lancet 381 2013 537 545
17. AV Chobanian, GL Bakris, HR Black et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
18. G Mancia, G De Backer, A Dominiczak et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 28 2007 1462 1536
19. JA Jordan, SA Engeli, JB Redon et al. European Society of Hypertension Working Group on Obesity: background, aims and perspectives J Hypertens 25 2007 897 900
20. WHO International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments J Hypertens 16 1998 127 137
21. MJ Domanski, KA Jablonski, MM Rice, SE Fowler, E Braunwald Obesity and cardiovascular events in patients with established coronary disease Eur Heart J 27 2006 1416 1422
22. S Kenchaiah, SJ Pocock, D Wang et al. Body mass index and prognosis in patients with chronic heart failure: insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program Circulation 116 2007 627 636
23. C Kragelund, C Hassager, P Hildebrandt, C Torp-Pedersen, L Kober TRACE study group Impact of obesity on long-term prognosis following acute myocardial infarction Int J Cardiol 98 2005 123 131
24. M Haass, DW Kitzman, IS Anand et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial Circ Heart Fail 4 2011 324 331
25. JI Barzilay, AG Howard, GW Evans et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial Diabetes Care 35 2012 1401 1405
26. Y Kawano, T Ogihara, T Saruta, Y Goto, M Ishii Association of blood pressure control and metabolic syndrome with cardiovascular risk in elderly Japanese: JATOS study Am J Hypertens 24 2011 1250 1256
27. V Charlon, I Kobrin The efficacy and safety of mibefradil in subgroups of patients with chronic stable angina pectoris Int J Clin Pract 52 1998 257 264
28. S Uretsky, FH Messerli, S Bangalore et al. Obesity paradox in patients with hypertension and coronary artery disease Am J Med 120 2007 863 870
29. HDFP Mortality findings for stepped-care and referred-care participants in the hypertension detection and follow-up program, stratified by other risk factors. The Hypertension Detection and Follow-up Program Cooperative Research Group Prev Med 14 1985 312 335
30. H Irie, J Shiraishi, T Sawada, M Koide, H Yamada, H Matsubara Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with overweight/obesity: a post-hoc analysis of the KYOTO HEART Study Int J Cardiol 2012 10.1016/j.ijcard.2012.06.103 published online July 12.
31. S Wassertheil-Smoller, C Fann, RM Allman et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group Arch Intern Med 160 2000 494 500
32. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) JAMA 283 2000 1967 1975
33. JPT Higgins, DG Altman, PC Gøtzsche et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
34. WHO Obesity: preventing and managing the global epidemic. Report of a WHO consultation World Health Organ Tech Rep Ser 894 2000 i xii 1-253.
35. J Schrader, S Lüders, A Kulschewski et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES) Stroke 36 2005 1218 1224
36. NS Beckett, R Peters, AE Fletcher et al. Treatment of hypertension in patients 80 years of age or older N Engl J Med 358 2008 1887 1898
37. F Mallamaci, P Ruggenenti, A Perna et al. ACE inhibition is renoprotective among obese patients with proteinuria J Am Soc Nephrol 22 2011 1122 1128
38. F Turnbull, B Neal, T Ninomiya et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials BMJ 336 2008 1121 1123
39. F Turnbull, M Woodward, B Neal et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials Eur Heart J 29 2008 2669 2680
40. S Czernichow, A Zanchetti, F Turnbull et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials J Hypertens 29 2011 4 16
41. Prospective Studies Collaboration Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies Lancet 373 2009 1083 1096
42. AW Krug, M Ehrhart-Bornstein Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 51 2008 1252 1258